Intervet Inc.

Intervet International B.v.

Melanie Sno

Vicky Fachinger

Maarten Hendrik Witvliet

Antonius Arnoldus Christiaan Jacobs

Ruud Philip Antoon Maria Segers

Erwin Van Den Born

Erwin Born Van Den

Chen Shu-hui Tan

Erik Cox

Pieter Van Gelder

The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 and live attenuated PRRS virus for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus by administration of the vaccine into the dermis of the animal.

Vaccine for intradermal application against PCV2 and PRRS virus infection

The present invention pertains to a combination of a first vaccine comprising non-replicating immunogen of porcine circo virus type 2 (PCV2) and non-replicating immunogen of, and a second vaccine comprising live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating an animal against an infection with porcine circovirus type 2, an infection withand an infection with PRRS virus, by associated non-mixed administration of the first vaccine and the second vaccine to the animal. The invention also pertains to a kit-of-parts comprising the first and second vaccine and to a method of protecting an animal against such infections using these vaccines.

Vaccines containing swine pathogens for associated non-mixed use

The invention pertains to a vaccine comprising in combination non-replicating immunogens of, porcine parvo virus,and live attenuated PRRS virus, and a pharmaceutically acceptable carrier, for use in a method for prophylactic treatment of a swine against an infection with, porcine parvo virus,and PRRS virus, wherein the vaccine is administered in a single dose with regard to the treatment against an infection with PRRS virus.

Swine vaccine

The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 &#x3bc;g per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.

Vaccine comprising a PCV2 ORF2 protein of genotype 2b

The present invention pertains to a vaccine for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus, the vaccine comprising in combination non-replicating immunogen of porcine circovirus type 2 and live attenuated PRRS virus, wherein the vaccine additionally comprises albumin.

Combination vaccine against PCV2 and PRRS virus infection comprising albumin

The present invention pertains to a vaccine comprising in combination killed whole cell Lawsonia intracellularis bacteria and porcine circo virus 2 (PCV2) ORF2 protein for use in protecting a pig against an infection with Lawsonia intracellularis and PCV2 by an intradermal administration of the vaccine. The invention also pertains to a method to protect a swine against an infection with Lawsonia intracellularis bacteria and PCV2.

Vaccine against Lawsonia intracellularis and porcine circovirus 2

The present invention pertains to a vaccine comprising a non-replicating immunogen of porcine circo virus type 2 for use in prophylactically treating an animal that has circulating antibodies directed against porcine circo virus type 2, against an infection with pathogenic porcine circo virus type 2 by a single dose administration of the vaccine into the dermis of the animal.

Vaccine against porcine circo virus type 2

The present invention relates to methods for the release of baculovirus-expressed Virus-like Particles (VLP's) of non-enveloped viruses from insect cells.

Growing community of inventors

Venlo, Netherlands

Melanie Sno